Experienced in Liposarcoma

Dr. Danko Martincic

Hematology | Oncology
Beacon Cancer Care PLLC
3815 N Schreiber Way, Unit 101, 
Coeur D Alene, ID 
Offers Telehealth
Experienced in Liposarcoma
Beacon Cancer Care PLLC
3815 N Schreiber Way, Unit 101, 
Coeur D Alene, ID 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Danko Martincic is a Hematologist and an Oncologist in Coeur D Alene, Idaho. Dr. Martincic is rated as an Experienced provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Multiple Myeloma, Familial Colorectal Cancer, Lung Cancer, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in ID
Hospital Affiliations
Northwest Specialty Hospital
Shoshone Medical Center
Bonner General Hospital
Kootenai Health
Benewah Community Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PacificSource
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

BEACON CANCER CARE PLLC
3815 N Schreiber Way, Unit 101, Coeur D Alene, ID 83815

Additional Areas of Focus

Dr. Martincic has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
A Phase 2, Randomized, Open-Label Study of Trilaciclib Administered With First-Line Platinum-Based Chemotherapy and Avelumab Maintenance Therapy in Patients With Untreated, Locally Advanced or Metastatic Urothelial Carcinoma (PRESERVE 3)
Enrollment Status: Terminated
Publish Date: September 08, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Cisplatin, Carboplatin, Avelumab
Study Phase: Phase 2
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: November 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: September 18, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer
Enrollment Status: Withdrawn
Publish Date: July 31, 2017
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

3 Total Publications

Overall survival analysis of adjuvant radiation versus observation in stage I testicular seminoma: a surveillance, epidemiology, and end results (SEER) analysis.
Overall survival analysis of adjuvant radiation versus observation in stage I testicular seminoma: a surveillance, epidemiology, and end results (SEER) analysis.
Journal: American journal of clinical oncology
Published: July 12, 2012
Similar Doctors
Advanced in Liposarcoma
Dr. Brian L. Samuels
Hematology Oncology | Oncology
Advanced in Liposarcoma
Dr. Brian L. Samuels
Hematology Oncology | Oncology
980 W Ironwood Dr Ste 207, 
Coeur D Alene, ID 
 (8.0 miles away)
208-755-2804
Languages Spoken:
English

Brian Samuels is a Hematologist Oncology specialist and an Oncologist in Coeur D Alene, Idaho. Dr. Samuels is rated as an Advanced provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Epithelioid Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Liposarcoma, and Bone Tumor.

Advanced in Liposarcoma
Dr. David C. Bartels
Hematology Oncology | Hematology | Oncology
Advanced in Liposarcoma
Dr. David C. Bartels
Hematology Oncology | Hematology | Oncology

Beacon Cancer Care PLLC

3815 N Schreiber Way, Unit 101, 
Coeur D Alene, ID 
 (0.1 miles away)
208-755-2804
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Bartels is a Hematologist Oncology specialist and a Hematologist in Coeur D Alene, Idaho. Dr. Bartels is rated as a Distinguished provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Malignant Peripheral Nerve Sheath Tumor, Familial Colorectal Cancer, Paget Disease of the Breast, and Colorectal Cancer. Dr. Bartels is currently accepting new patients.

Experienced in Liposarcoma
Dr. Kevin P. Mulvey
Hematology Oncology | Oncology | Hematology
Experienced in Liposarcoma
Dr. Kevin P. Mulvey
Hematology Oncology | Oncology | Hematology

Kootenai Health Inc

1440 E Mullan Ave, 
Post Falls, ID 
 (6.4 miles away)
208-625-4900
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Kevin Mulvey is a Hematologist Oncology specialist and an Oncologist in Post Falls, Idaho. Dr. Mulvey is rated as a Distinguished provider by MediFind in the treatment of Liposarcoma. His top areas of expertise are Follicular Lymphoma, Large-Cell Immunoblastic Lymphoma, Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration. Dr. Mulvey is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Martincic's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 21 Advanced Conditions
    View All 91 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile